Search Results Label

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-announces-late-breaking-data-at-idweek-2020

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-presents-new-real-world-evidence-on-relative-effectiveness

Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market

https://www.seqirus.us/news/seqirus-ships-2020-2021-influenza-vaccines-to-us-market

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-publishes-new-real-world-evidence

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-presents-first-of-its-kind-study-on-cell-based-quadrivalent-influenza-vaccine

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/seqirus-real-world-evidence-published

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news

Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older

https://www.seqirus.us/news/seqirus-receives-fda-approval-for-fluad-quadrivalent-for-adults-65-years-and-older

Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.

https://www.seqirus.us/partnering

Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.

https://www.seqirus.us/